CTKB
What one share of Cytek Biosciences holds
Laboratory Analytical Instruments
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology).
Cytek Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.61 |
|---|---|
| Profit | −$0.63 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$0.09 |
| Cash and investments | $0.57 |
| Debt | $0.00 |
| Book value | $2.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.02 | $0.10 | $0.05 | $0.42 | — | −$0.51 |
| 2021 | $0.03 | $0.00 | $0.05 | $0.00 | — | $3.03 |
| 2022 | $0.02 | $0.02 | $0.07 | −$0.16 | — | $3.14 |
| 2023 | $1.43 | −$0.09 | $0.03 | $0.00 | — | $3.01 |
| 2024 | $1.53 | −$0.05 | $0.03 | $0.17 | — | $3.06 |
| 2025 | $1.58 | −$0.52 | $0.03 | −$0.07 | — | $2.66 |